Searie’s DayPro
Executive Summary
Two years of additional market exclusivity for Searie's nonsteroidal anti-inflammatory drug DayPro (oxaprozin) would be provided under legislation (S 1734, HR 3552) introduced Nov. 19 by Sens. Simon (D-Ill.), Hatch (R-Utah) and Moseley-Braun (D-Ill.) in the Senate and by Rep. Collins (D-Ill.) in the House. The additional exclusivity, beyond the five years granted under the Waxman/Hatch Act, is being sought to compensate for the time that elapsed between Searie's NDA submission Aug. 10, 1982 and DayPro's approval Oct. 29, 1992.